- Home
- MRKR vs TURN Comparison
MRKR vs TURN Comparison
Compare MRKR & TURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRKR
- TURN
- Stock Information
- Founded
- MRKR N/A
- TURN 1981
- Country
- MRKR United States
- TURN United States
- Employees
- MRKR N/A
- TURN N/A
- Industry
- MRKR Biotechnology: Pharmaceutical Preparations
- TURN Finance/Investors Services
- Sector
- MRKR Health Care
- TURN Finance
- Exchange
- MRKR Nasdaq
- TURN Nasdaq
- Market Cap
- MRKR 27.7M
- TURN 33.3M
- IPO Year
- MRKR N/A
- TURN N/A
- Fundamental
- Price
- MRKR $3.26
- TURN $3.44
- Analyst Decision
- MRKR Strong Buy
- TURN
- Analyst Count
- MRKR 1
- TURN 0
- Target Price
- MRKR $19.00
- TURN N/A
- AVG Volume (30 Days)
- MRKR 29.1K
- TURN 32.3K
- Earning Date
- MRKR 11-14-2024
- TURN 12-10-2024
- Dividend Yield
- MRKR N/A
- TURN N/A
- EPS Growth
- MRKR N/A
- TURN N/A
- EPS
- MRKR N/A
- TURN N/A
- Revenue
- MRKR $5,395,849.00
- TURN $129,297.00
- Revenue This Year
- MRKR $35.94
- TURN N/A
- Revenue Next Year
- MRKR N/A
- TURN N/A
- P/E Ratio
- MRKR N/A
- TURN N/A
- Revenue Growth
- MRKR 79.04
- TURN 6.32
- 52 Week Low
- MRKR $2.44
- TURN $3.12
- 52 Week High
- MRKR $6.16
- TURN $4.47
- Technical
- Relative Strength Index (RSI)
- MRKR 46.38
- TURN 58.13
- Support Level
- MRKR $2.82
- TURN $3.24
- Resistance Level
- MRKR $3.60
- TURN $3.35
- Average True Range (ATR)
- MRKR 0.39
- TURN 0.11
- MACD
- MRKR -0.06
- TURN 0.02
- Stochastic Oscillator
- MRKR 27.85
- TURN 45.92
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.